Biologics in oral medicine: Ulcerative disorders

Oral Diseases

Volumn 19, Issue 1, 2013, Pages 37-45

  O'Neill, I D ^a   Scully, C ^b  

^a Centre d'Affaires Poincare   (France)

^b WHO Collaborating Centre for Oral Health General Health and University College London   (United Kingdom)

Author keywords

Aphthae; Aphthous ulceration; Behcet; Biologics; Etanercept; Infliximab; Lichen planus; Rituximab; Tumour necrosis factor; Vesiculobullous

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; RITUXIMAB;

APHTHOUS ULCER; BEHCET DISEASE; BULLOUS PEMPHIGOID; CONSENSUS; DISEASE DURATION; DRUG EFFICACY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LICHEN PLANUS; MOUTH MUCOSA; MOUTH ULCER; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PEMPHIGUS VULGARIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMATOLOGY; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; BIOLOGICAL PRODUCTS; BLISTER; HUMANS; IMMUNOLOGIC FACTORS; LICHEN PLANUS, ORAL; ORAL ULCER; STOMATITIS, APHTHOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870732055     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2012.01931.x     Document Type: Review

References (113)

1. Ahmed AR, Spigelman Z, Cavacini LA, Poster MR (2006). Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med355: 1772-1779.
2. Aikawa NE, Gonçalves C, Silva CA, Gonçalves C, Bonfá E, de Carvalho JF (2011). Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease. Rheumatol Int31: 1097-1099.
3. Almoznino G, Ben-Chetrit E (2007). Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature. Clin Exp Rheumatol25: S99-S102.
4. Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011). Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum41: 61-70.
5. Asarch A, Gottlieb AB, Lee J et al (2009). Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor alpha antagonists. J Am Acad Dermatol61: 104-111.
6. Atzeni F, Sarzi-Puttini P, Capsoni F, Mecchia M, Marrazza MG, Carrabba M (2005). Successful treatment of resistant Behçet's disease with etanercept. Clin Exp Rheumatol23: 729.
7. Baccaglini L, Lalla R, Bruce A et al (2011). Urban legends series: recurrent aphthous stomatitis. Oral Dis17: 755-770.
8. Berookhim B, Fischer HD, Weinberg JM (2004). Treatment of recalcitrant pemphigus vulgaris with tumor necrosis factor alpha antagonist etanercept. Cutis74: 245-247.
9. Bombeccari GP, Guzzi G, Tettamanti M et al (2011). Oral lichen planus and malignant transformation: a longitudinal cohort study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod112: 328-334.
10. Bordignon M, Belloni-Fortina A, Pigozzi B, Tarantello M, Alaibac M (2009). Bullous pemphigoid during long-term TNF-alpha blocker therapy. Dermatology219: 357-358.
11. Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A (2001). Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol137: 269-272.
12. Boussemart L, Jacobelli S, Batteux F et al (2010). Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology221: 201-205.
13. Bruce A, Rogers RS III (2007). New and old therapeutics for oral ulcerations. Arch Dermatol143: 519-523.
14. Buch MH, Smolen JS, Betteridge N et al (2011). Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis70: 909-920.
15. Calvo Catalá J, Campos Fernández C, Rueda Cid A, González-Cruz Cervellera MI, Baixauli Rubio A, Pastor Cubillo MD (2011). [Efficacy of adalimumab in Behçet's disease. Description of 6 cases]. Reumatol Clin7: 258-261.
16. Canizares MJ, Smith DI, Conners MS, Maverick KJ, Heffernan MP (2006). Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol142: 1457-1461.
17. Cavailhes A, Balme B, Gilbert D, Skowron F (2009). [Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita]. Ann Dermatol Venereol136: 795-799.
18. Chang AL, Badger J, Rehmus W, Kimball AB (2008). Alefacept for erosive lichen planus: a case series. J Drugs Dermatol7: 379-383.
19. Chao TJ (2009). Adalimumab in the management of cutaneous and oral lichen planus. Cutis84: 325-328.
20. Cheng A, Mann C (2006). Oral erosive lichen planus treated with efalizumab. Arch Dermatol142: 680-682.
21. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P (2007). Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol143: 1033-1038.
22. Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pità O (2012). Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol doi: 10.1016/j.jaad.2011.11.007 [Epub ahead of print].
23. Cirillo N, Cozzani E, Carrozzo M, Grando S (2012). Urban legends: pemphigus vulgaris. Oral Dis doi: 10.1111/j.1601-0825.2011.01899.x [Epub ahead of print].
24. Connolly M, Armstrong JS, Buckley DA (2005). Infliximab treatment for severe orogenital ulceration in Behçet's disease. Br J Dermatol153: 1073-1075.
25. Craythorne E, du Viver A, Mufti GJ, Warnakulasuriya S (2011). Rituximab for the treatment of corticosteroid - refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med40: 616-620.
26. Crichlow SM, Mortimer NJ, Harman KE (2007). A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol156: 194-196.
27. Curigliano V, Giovinale M, Fonnesu C et al (2008). Efficacy of etanercept in the treatment of a patient with Behçet's disease. Clin Rheumatol27: 933-966.
28. Daulat S, Detweiler JG, Pandya AG (2009). Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. J Eur Acad Dermatol Venereol23: 483-484.
29. D'Haens GR, Panaccione R, Higgins PD et al (2011). The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Am J Gastroenterol106: 199-212.
30. Elliott E, Campbell H, Escudier M et al (2011). Experience with anti-TNF-α therapy for orofacial granulomatosis. J Oral Pathol Med40: 14-19.
31. Estrach C, Mpofu S, Moots RJ (2002). Behcet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford)41: 1213-1214.
32. Feldman RJ, Ahmed AR (2011). Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol7: 529-541.
33. Fiorentino DF, Garcia MS, Rehmus W, Kimball AB (2011). A pilot study of etanercept treatment for pemphigus vulgaris. Arch Dermatol147: 117-118.
34. Fivenson DP, Mathes B (2006). Treatment of generalized lichen planus with alefacept. Arch Dermatol142: 151-1522.
35. Fuertes I, Guilabert A, Mascaró JM Jr, Iranzo P (2010). Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature. Dermatology221: 13-16.
36. Furst DE, Keystone EC, Braun J et al (2011). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis70(Suppl 1): i2-i36.
37. Geissal ED, Wernick R (2010). A case of severe MAGIC syndrome treated successfully with the tumor necrosis factor-alpha inhibitor infliximab. J Clin Rheumatol16: 185-187.
38. Goossens PH, Verburg RJ, Breedveld FC (2001). Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis60: 637.
39. Hatemi G, Silman A, Bang D et al (2008). EULAR recommendations for the management of Behçet disease. Ann Rheum Dis67: 1656-1662.
40. Heffernan MP, Bentley DD (2006). Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol142: 1268-7120.
41. Heffernan MP, Smith DI, Bentley D, Tabacchi M, Graves JE (2007). A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus. J Drugs Dermatol6: 310-314.
42. Hello M, Barbarot S, Bastuji-Garin S, Revuz J, Chosidow O (2010). Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis. Medicine (Baltimore)89: 176-182.
43. Herrmann G, Hunzelmann N, Engert A (2003). Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol148: 602-603.
44. Hertl M, Zillikens D, Borradori L et al (2008). Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges6: 366-373.
45. Hertl M, Bernard P, Borradori L (2011). Rituximab for severe mucous membrane pemphigoid: safe enough to be drug of first choice?Arch Dermatol147: 855-856.
46. Ho JK, Hantash BM (2011). Treatment of recalcitrant vulvovaginal gingival syndrome with adalimumab. J Am Acad Dermatol65: e55-e77.
47. Jacobi A, Shuler G, Hertl M (2005). Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol153: 448-449.
48. Jacobi A, Debus D, Schuler G, Hertl M (2008). Infliximab in a patient with refractory mucosal aphthosis. J Eur Acad Dermatol Venereol22: 109-110.
49. Jensen AØ, Møller BK, Vangkilde A et al (2009). Treatment of treatment-resistant autoimmune blistering skin disorders with rituximab. Br J Dermatol160: 1359-1361.
50. Joly P, Mouquet H, Roujeau JC et al (2007). A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med357: 545-552.
51. Kaneko U, Kishi T, Kikuchi M et al (2010). [Two patients with childhood-onset Behcet's disease successfully treated by anti-tumor necrosis factor therapy]. Nihon Rinsho Meneki Gakkai Kaishi33: 157-161.
52. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E (2011). Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol65: 552-558.
53. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O (2005). The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int25: 406-410.
54. Kennedy JS, Devillez RL, Henning JS (2010). Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept. J Drugs Dermatol9: 68-70.
55. Kim JH, Kim YH, Kim MR, Kim SC (2011). Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol165: 646-651.
56. Korman BD, Tyler KL, Korman NJ (2009). Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol145: 937-942.
57. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM (2007). Adalimumab: a new modality for Behçet's disease?Ann Rheum Dis66: 565-666.
58. Le Roux-Villet C, Prost-Squarcioni C, Alexandre M et al (2011). Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol147: 843-849.
59. Li Y, Foshee JB, Sontheimer RD (2011). Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease. J Am Acad Dermatol64: 773-778.
60. Lin MH, Hsu CK, Lee JY (2005). Successful treatment of the recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol141: 680-682.
61. Lodi G, Pellicano R, Carrozzo M (2010). Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis. Oral Dis16: 601-612.
62. Lourari S, Herve C, Doffoel-Hantz V et al (2011). Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol25: 1238-1240.
63. Mariette X, Gottenberg JE, Ravaud P, Combe B (2011). Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford)50: 222-229.
64. Martin LK, Werth VP, Villaneuva EV, Murrell DF (2011). A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol64: 903-908.
65. Melikoglu M, Fresko I, Mat C et al (2005). Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol32: 98-105.
66. Muller S, McCreary C, Murphy M (2008). Vulvovaginal-gingival lichen planus with initial response to infliximab. Irish Association of Dermatologists Spring meeting (Abstract 08).
67. Nedjai B, Quillinan N, Coughlan RJ et al (2011). Lessons from anti-TNF biologics: infliximab failure in a TRAPS family with the T50M mutation in TNFRSF1A. Adv Exp Med Biol691: 409-419.
68. Ng WF, Bowman SJ, Griffiths B; UKPSSR Study Group (2011). United Kingdom Primary Sjogren's Syndrome Registry-a united effort to tackle an orphan rheumatic disease. Reumatology (Oxford)50: 32-39.
69. Niedermeier A, Eming R, Pfütze M et al (2006). Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol143: 192-198.
70. Olivieri I, Latanza L, Siringo S, Peruz G, Di Iorio V (2008). Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete. J Rheumatol35: 930-932.
71. Olivieri I, Padula A, Leccese P, D'Angelo S, Giasi V (2009). Long-lasting remission of severe Behçet's disease after the end of infliximab therapy. J Rheumatol36: 855.
72. O'Neill ID (2008). Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med37: 575-581.
73. O'Neill I (2010). Guidance on the use of biological agents in the treatment of oral mucosal disease. Br J Dermatol162: 1410-1411.
74. O'Neill ID (2012). Efficacy of tumour necrosis factor-alpha antagonists in aphthous ulceration: review of published individual patient data. J Eur Acad Dermatol Venereol26: 231-235.
75. O'Neil ID, Scully C (2012). Biologics in oral medicine: principles of use and practical considerations. Oral Dis doi: 10.1111/j.1601-0825.2012.01919.x.
76. Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM (2005). Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol153: 222-223.
77. Parmentier L, Bron BA, Prins C, Samson J, Masouyé I, Borradori L (2008). Mucocutaneous lichen planus with esophagal involvement: successful treatment with an anti-CD20 monoclonal antibody. Arch Dermatol144: 1427-1430.
78. Peterson JD, Chan LS (2009). Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: a comprehensive survey of 71 consecutive patients from the Initial use to 2007. Ther Clin Risk Manag5: 1-7.
79. Petti S, Rabiei M, De Luca M, Scully C (2011). The magnitude of the association between hepatitis C virus infection and oral lichen planus: meta-analysis and case control study. Odontology99: 168-178.
80. Prignano F, Ricceri F, Pescitelli L, Zanieri F, Lotti T (2011). Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol64: 645-647.
81. Rahman N, Healy C, Flint SR, Stassen LF (2010). Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening. J Clin Rheumatol16: 197-199.
82. Rebora A, Parodi A, Murialdo G (2002). Basiliximab is effective for erosive lichen planus. Arch Dermatol138: 1100-1101.
83. Robertson LP, Hickling P (2001). Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford)40: 473-474.
84. Robinson ND, Guitart J (2003). Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol139: 1259-1262.
85. Rousseau A, Taberne R, Siberchicot F, Fricain JC, Zwetyenga N (2009). [Cancer of the cheek in a patient under etanercept]. Rev Stomatol Chir Maxillofac110: 306-308.
86. Sacher C, Rubbert A, Konig C, Scharffetter-Kochanek K, Krieg T, Hunzelmann N (2002). Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol46: 113-115.
87. Sadler E, Schafleitner B, Lanschuetzer C et al (2007). Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol157: 417-419.
88. Saha M, Cutler T, Bhogal B, Black MM, Groves RW (2009). Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. Clin Exp Dermatol34: e979-e980.
89. Sánchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Ortego-Centeno N (2009). Recalcitrant, recurrent aphthous stomatitis successfully treated with adalimumab. J Eur Acad Dermatol Venereol23: 206.
90. Sankar V, Hearnden V, Hull K et al (2011). Local drug delivery for oral mucosal diseases: challenges and opportunities. Oral Dis17(Suppl 1): 73-84.
91. Saulsbury FT, Mann JA (2003). Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum49: 599-600.
92. Scheinberg MA (2002). Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol20: 733-734.
93. Schmidt E, Zillikens D (2011). The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int108: 399-405.
94. Schmidt E, Benoit S, Bröcker E-B, Zillikens D, Goebeler M (2006). Successful treatment of recalcitrant epidermolysis bullosa acquisita with rituximab. Arch Dermatol142: 47-50.
95. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M (2007). Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol156: 352-356.
96. Scully C (2006). Clinical practice. Aphthous ulceration. N Engl J Med355: 165-172.
97. Scully C, Carrozzo M (2008). Oral mucosal disease: lichen planus. Br J Oral Maxillofac Surg46: 15-21.
98. Scully C, Hodgson T (2008). Recurrent oral ulceration: aphthous-like ulcers in periodic syndromes. Oral Surg Oral Med Oral Pathol Oral Radiol Endod106: 845-852.
99. Scully C, Hodgson T, Lachmann H (2008). Auto-inflammatory syndromes and oral health. Oral Dis14: 690-699.
100. Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007). Anti-TNF therapy in the management of Behçet's disease - review and basis for recommendations. Rheumatology (Oxford)46: 736-741.
101. Shetty A, Marcum CB, Glass LF, Carter JD (2009). Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol8: 940-943.
102. Smith CH, Anstey AV, Barker JN et al (2009). British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol161: 987-1019.
103. Sommer A, Altmeyer P, Kreuter A (2005). A case of mucocutaneous Behçet's disease responding to etanercept. J Am Acad Dermatol52: 717-719.
104. Streit M, Beleznay Z, Braathen LR (2006). Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J3: 171-179.
105. Tam A, Anderson DA (2007). The treatment of lower leg ulcers with topical etanercept. J Am Osteopath Coll Dermatol8: 68-71.
106. Vujevich J, Zirwas M (2005). Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab. Cutis76: 129-132.
107. Wallet-Faber N, Franck N, Batteux F et al (2007). Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology215: 252-255.
108. Wolfe F, Michaud K (2011). The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology (Oxford)50: 16-24.
109. Wu Y, Zhou G, Zeng H, Xiong CR, Lin M, Zhou HM (2010). A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod110: 188-195.
110. Yarom N (2007). Etanercept for the management of oral lichen planus. Am J Clin Dermatol8: 121.
111. Zhang J, Zhou G, Du GF, Xu XY, Zhou HM (2011). Biologics, an alternative therapeutic approach for oral lichen planus. J Oral Pathol Med40: 521-524.
112. Zone JJ (2011). Taking responsibility for complex medical dermatology patient management: comment on "rituximab for patients with refractory mucous membrane pemphigoid". Arch Dermatol147: 850.
113. ®). J Eur Acad Dermatol Venereol21: 1286-1287.